Halozyme Therapeutics HALO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 82.8%-0.7pp | 83.6%-0.7pp | 84.5%+2.5pp | 84.2%+4.2pp | 83.4%+4.9pp | |
| Free cash flow margin | 44.3%-1.5pp | 46.2%0.0pp | 48.5%+7.0pp | 45.9%-0.9pp | 45.7%-3.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.1× | 0.6×+0.1× | 0.6×+0.1× | 0.6×+0.1× | 0.5×0.0× | |
| Inventory turnover | 10.8×+9.0× | 6×— | 4.4×+2.6× | 5.9×+3.7× | 1.8×+0.4× | |
| Liquidity | ||||||
| Current ratio | 2.8×-5.6× | 4.7×-3.1× | 1.6×-8.8× | 8.4×+1.0× | 8.4×+1.8× | |
| Quick ratio | 2.7×-5.4× | 4.5×-2.9× | 1.6×-8.3× | 8.1×+0.9× | 8.2×+2.8× | |
| Cash ratio | 0.9×-0.3× | 0.8×-0.1× | 0.5×-0.9× | 0.5×-0.9× | 1.2×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 9.9×+6.7× | 44.6×+40.4× | 3.1×-0.3× | 4.6×-0.7× | 3.2×-5.4× | |
| Debt-to-assets | 0.8×+0.1× | 0.9×+0.1× | 0.7×0.0× | 0.7×0.0× | 0.7×-0.1× | |
| Per Share | ||||||
| Book value per share | $1.79-53.1% | $0.39-86.0% | $4.12+18.4% | $2.68+19.7% | $3.81+176% | |
| Valuation | ||||||
| Market capitalization | $7.66B-2.9% | $7.91B+30.1% | $8.58B+17.9% | $6.64B-0.1% | $7.88B+52.6% | |
| Enterprise value | $9.52B+3.0% | $9.96B+32.7% | $9.7B+12.0% | $8.12B+1.6% | $9.24B+41.5% | |
| Price / sales | 5.1×-2.2× | 5.7×-0.3× | 6.9×-0.8× | 5.6×-2.0× | 7.3×+1.3× | |
| Price / book | 34.9×+18.5× | 162.1×+145× | 17×+1.0× | 20×-3.0× | 16.3×-12.7× | |
| EV / sales | 6.3×-2.2× | 7.1×-0.3× | 7.8×-1.3× | 6.9×-2.3× | 8.5×+1.0× | |
| Free cash flow yield | 8.7%+2.4pp | 8.1%+0.4pp | 7%+1.6pp | 8.1%+2.0pp | 6.3%-1.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Halozyme Therapeutics's profit margins?
- Halozyme Therapeutics (HALO) runs a 82.8% gross margin and a 59.3% operating margin, with a 47.9% net margin.
- Where do Halozyme Therapeutics's ratios come from?
- Every ratio is computed from Halozyme Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
